Tumor-Derived Exosomal miR-620 as a Diagnostic Biomarker in Non-Small-Cell Lung Cancer
Youyong Tang
Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China sdams.cn
Search for more papers by this authorZhijun Zhang
Department of Clinical Laboratory, Taian City Central Hospital, Taian, China taishanyy.com
Search for more papers by this authorXingguo Song
Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China sdams.cn
Search for more papers by this authorMiao Yu
Department of Clinical Laboratory, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China sdu.edu.cn
Search for more papers by this authorLimin Niu
Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China sdams.cn
Search for more papers by this authorYajing Zhao
Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China sdams.cn
Search for more papers by this authorLi Wang
Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China sdams.cn
Search for more papers by this authorXianrang Song
Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China sdams.cn
Search for more papers by this authorCorresponding Author
Li Xie
Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China sdams.cn
Search for more papers by this authorYouyong Tang
Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China sdams.cn
Search for more papers by this authorZhijun Zhang
Department of Clinical Laboratory, Taian City Central Hospital, Taian, China taishanyy.com
Search for more papers by this authorXingguo Song
Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China sdams.cn
Search for more papers by this authorMiao Yu
Department of Clinical Laboratory, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China sdu.edu.cn
Search for more papers by this authorLimin Niu
Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China sdams.cn
Search for more papers by this authorYajing Zhao
Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China sdams.cn
Search for more papers by this authorLi Wang
Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China sdams.cn
Search for more papers by this authorXianrang Song
Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China sdams.cn
Search for more papers by this authorCorresponding Author
Li Xie
Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China sdams.cn
Search for more papers by this authorAbstract
Background. Evidence has suggested the functional role of exosomal miRNAs in cancer diagnosis. This study aimed to determine whether the serum exosomal biomarkers can improve the diagnosis of patients with non-small-cell lung cancer (NSCLC). Materials and Methods. The exosomes were extracted from the serum of NSCLC patients (n = 235) and healthy donors (n = 231) using ultracentrifugation and then were evaluated by using transmission electron microscopy, qNano, and western blotting. The serum exosomal miRNA expression was validated using qPCR. Results. Exosomal miR-620 was significantly reduced in NSCLC and early-stage NSCLC patients (P < 0.0001) when compared to that of healthy controls, with an area under the curve (AUC) of 0.728 and 0.707, respectively. Exosomal miR-620 expression showed an association with drinking (P = 0.008) and distant metastasis (P = 0.037). Additionally, the downregulated exosomal miR-620 showed association with chemotherapeutic effect (P = 0.044). Conclusion. These findings suggest the serum exosomal miR-620 as a promising diagnostic and prognostic noninvasive biomarker in NSCLC patients.
Conflicts of Interest
The authors declare that there are no conflicts of interest.
Open Research
Data Availability
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
References
- 1 Siegel R. L., Miller K. D., and Jemal A., Cancer statistics, 2020, CA: A Cancer Journal for Clinicians. (2020) 70, no. 1, 7–30, https://doi.org/10.3322/caac.21590.
- 2 Zappa C. and Mousa S. A., Non-small cell lung cancer: current treatment and future advances, Translational Lung Cancer Research. (2016) 5, no. 3, 288–300, https://doi.org/10.21037/tlcr.2016.06.07, 2-s2.0-84977470126.
- 3 Simeone J. C., Nordstrom B. L., Patel K., and Klein A. B., Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting, Future Oncology. (2019) 15, no. 30, 3491–3502, https://doi.org/10.2217/fon-2019-0348, 2-s2.0-85074119272.
- 4 Lässer C., Seyed Alikhani V., Ekström K. et al., Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages, Journal of Translational Medicine. (2011) 9, no. 1, https://doi.org/10.1186/1479-5876-9-9, 2-s2.0-78651361232.
- 5 Li J., Liu K., Liu Y. et al., Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity, Nature Immunology. (2013) 14, no. 8, 793–803, https://doi.org/10.1038/ni.2647, 2-s2.0-84880797948.
- 6 Tsukamoto M., Iinuma H., Yagi T., Matsuda K., and Hashiguchi Y., Circulating exosomal MicroRNA-21 as a biomarker in each tumor stage of colorectal cancer, Oncology. (2017) 92, no. 6, 360–370, https://doi.org/10.1159/000463387, 2-s2.0-85017134879.
- 7 Brunetti O., Russo A., Scarpa A. et al., MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?, Oncotarget. (2015) 6, no. 27, 23323–23341, https://doi.org/10.18632/oncotarget.4492, 2-s2.0-84943386886.
- 8 Gnoni A., Santini D., Scartozzi M. et al., Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?, Expert Opinion on Therapeutic Targets. (2015) 19, no. 12, 1623–1635, https://doi.org/10.1517/14728222.2015.1071354, 2-s2.0-84952876608.
- 9 Danza K., Silvestris N., Simone G. et al., Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance, Cancer Biology and Therapy. (2016) 17, no. 4, 400–406, https://doi.org/10.1080/15384047.2016.1139244, 2-s2.0-84966936571.
- 10 Koga Y., Yasunaga M., Moriya Y et al., Exosome can prevent RNase from degrading microRNA in feces, Journal of Gastrointestinal Oncology. (2011) 2, no. 4, 215–222, https://doi.org/10.3978/j.issn.2078-6891.2011.015.
- 11 Fan Q., Yang L., Zhang X. et al., The emerging role of exosome-derived non-coding RNAs in cancer biology, Cancer Letters. (2018) 414, 107–115, https://doi.org/10.1016/j.canlet.2017.10.040, 2-s2.0-85034444006.
- 12 Matsumura T., Sugimachi K., Iinuma H. et al., Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer, British Journal of Cancer. (2015) 113, no. 2, 275–281, https://doi.org/10.1038/bjc.2015.201, 2-s2.0-84937073193.
- 13 Joyce D. P., Kerin M. J., and Dwyer R. M., Exosome-encapsulated microRNAs as circulating biomarkers for breast cancer, International Journal of Cancer. (2016) 139, no. 7, 1443–1448, https://doi.org/10.1002/ijc.30179, 2-s2.0-84978180022.
- 14 Zhao Z., Yang Y., Zeng Y., and He M., A microfluidic ExoSearch chip for multiplexed exosome detection towards blood-based ovarian cancer diagnosis, Lab on a Chip. (2016) 16, no. 3, 489–496, https://doi.org/10.1039/c5lc01117e, 2-s2.0-84956734489.
- 15 Jin X., Chen Y., Chen H. et al., Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing, Clinical Cancer Research. (2017) 23, no. 17, 5311–5319, https://doi.org/10.1158/1078-0432.ccr-17-0577, 2-s2.0-85029455426.
- 16 Tang Y., Zhao Y., Song X., Song X., Niu L., and Xie L., Tumor-derived exosomal miRNA-320d as a biomarker for metastatic colorectal cancer, Journal of Clinical Laboratory Analysis. (2019) 33, no. 9, e23004, https://doi.org/10.1002/jcla.23004, 2-s2.0-85070738382.
- 17 Wang N., Guo W., Song X. et al., Tumor-associated exosomal miRNA biomarkers to differentiate metastatic vs. nonmetastatic non-small cell lung cancer, Clinical Chemistry and Laboratory Medicine. (2020) 58, no. 9, 1535–1545, https://doi.org/10.1515/cclm-2019-1329.
- 18 Finn R. S., Bengala C., Ibrahim N. et al., Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study, Clinical Cancer Research. (2011) 17, no. 21, 6905–6913, https://doi.org/10.1158/1078-0432.ccr-11-0288, 2-s2.0-80455173400.
- 19 Berindan-Neagoe I., Monroig P. D. C., Pasculli B., and Calin G. A., MicroRNAome genome: a treasure for cancer diagnosis and therapy, CA: A Cancer Journal for Clinicians. (2014) 64, no. 5, 311–336, https://doi.org/10.3322/caac.21244, 2-s2.0-84908125804.
- 20 Hollis M., Nair K., Vyas A., Chaturvedi L. S., Gambhir S., and Vyas D., MicroRNAs potential utility in colon cancer: early detection, prognosis, and chemosensitivity, World Journal of Gastroenterology. (2015) 21, no. 27, 8284–8292, https://doi.org/10.3748/wjg.v21.i27.8284, 2-s2.0-84938149539.
- 21 Matikas A., Syrigos K. N., and Agelaki S., Circulating biomarkers in non-small-cell lung cancer: current status and future challenges, Clinical Lung Cancer. (2016) 17, no. 6, 507–516, https://doi.org/10.1016/j.cllc.2016.05.021, 2-s2.0-84978374790.
- 22 Mitchell P. S., Parkin R. K., Kroh E. M. et al., Circulating microRNAs as stable blood-based markers for cancer detection, Proceedings of the National Academy of Sciences. (2008) 105, no. 30, 10513–10518, https://doi.org/10.1073/pnas.0804549105, 2-s2.0-48749122914.
- 23 Zhao Z., Han C., Liu J., Wang C., Wang Y., and Cheng L., GPC5, a tumor suppressor, is regulated by miR-620 in lung adenocarcinoma, Molecular Medicine Reports. (2014) 9, no. 6, 2540–2546, https://doi.org/10.3892/mmr.2014.2092, 2-s2.0-84899678612.
- 24 Li X. and Shen M., Circular RNA hsa_circ_103809 suppresses hepatocellular carcinoma proliferation and invasion by sponging miR-620, European Review for Medical and Pharmacological Sciences. (2019) 23, no. 2, 555–566, https://doi.org/10.26355/eurrev_201902_16868, 2-s2.0-85061038370.
- 25 Zhang C., Li H., Jiang W., Zhang X., and Li G., Icaritin inhibits the expression of alpha-fetoprotein in hepatitis B virus-infected hepatoma cell lines through post-transcriptional regulation, Oncotarget. (2016) 7, no. 50, 83755–83766, https://doi.org/10.18632/oncotarget.13194, 2-s2.0-85004190331.
- 26 El-Murr N., Abidi Z., Wanherdrick K. et al., MiRNA genes constitute new targets for microsatellite instability in colorectal cancer, PLoS One. (2012) 7, no. 2, e31862, https://doi.org/10.1371/journal.pone.0031862, 2-s2.0-84856896776.
- 27 Huang X., Taeb S., Jahangiri S. et al., miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD), Oncotarget. (2015) 6, no. 26, 22439–22451, https://doi.org/10.18632/oncotarget.4210, 2-s2.0-84941243541.
